104 related articles for article (PubMed ID: 28075460)
21. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
22. Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK.
Ang E; Liu Q; Qi M; Liu HG; Yang X; Chen H; Zheng MH; Xu J
J Cell Biochem; 2011 Jan; 112(1):89-97. PubMed ID: 20683903
[TBL] [Abstract][Full Text] [Related]
23. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
24. Dynein light chain LC8 inhibits osteoclast differentiation and prevents bone loss in mice.
Kim H; Hyeon S; Kim H; Yang Y; Huh JY; Park DR; Lee H; Seo DH; Kim HS; Lee SY; Jeong W
J Immunol; 2013 Feb; 190(3):1312-8. PubMed ID: 23293355
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis.
Ji X; Chen X; Yu X
Int J Mol Sci; 2016 Mar; 17(3):349. PubMed ID: 27005616
[TBL] [Abstract][Full Text] [Related]
26. [Molecules which are involved in osteoclastic bone resorption: from the aspect of targets of treatment for osteoporosis].
Take I; Takahash N; Kurihara S
Clin Calcium; 2005 May; 15(5):741-6. PubMed ID: 15876734
[TBL] [Abstract][Full Text] [Related]
27. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
28. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
[TBL] [Abstract][Full Text] [Related]
29. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
[TBL] [Abstract][Full Text] [Related]
30. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
31. RANKing intracellular signaling in osteoclasts.
Feng X
IUBMB Life; 2005 Jun; 57(6):389-95. PubMed ID: 16012047
[TBL] [Abstract][Full Text] [Related]
32. miR-218 is involved in the negative regulation of osteoclastogenesis and bone resorption by partial suppression of p38MAPK-c-Fos-NFATc1 signaling: Potential role for osteopenic diseases.
Qu B; Xia X; Yan M; Gong K; Deng S; Huang G; Ma Z; Pan X
Exp Cell Res; 2015 Oct; 338(1):89-96. PubMed ID: 26216483
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of differentiation and function of osteoclasts by dimethyl sulfoxide (DMSO).
Yang C; Madhu V; Thomas C; Yang X; Du X; Dighe AS; Cui Q
Cell Tissue Res; 2015 Dec; 362(3):577-85. PubMed ID: 26224539
[TBL] [Abstract][Full Text] [Related]
34. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
35. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
[TBL] [Abstract][Full Text] [Related]
36. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
37. Proteomic Analysis of Estrogen-Mediated Signal Transduction in Osteoclasts Formation.
Xiong Q; Tang P; Gao Y; Zhang L; Ge W
Biomed Res Int; 2015; 2015():596789. PubMed ID: 26120583
[TBL] [Abstract][Full Text] [Related]
38. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
39. Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways.
Ma X; Liu Y; Zhang Y; Yu X; Wang W; Zhao D
Biochem Biophys Res Commun; 2014 Mar; 445(2):282-8. PubMed ID: 24491533
[TBL] [Abstract][Full Text] [Related]
40. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
